Organization
TG Therapeutics
16 clinical trials
Clinical trial
Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects With Chronic Lymphocytic Leukemia (CLL)Status: Terminated, Estimated PCD: 2022-12-20
Clinical trial
A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab (ENHANCE)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1 First-in-Human Study of Bispecific Antibody TG-1801 in Subjects With B-Cell LymphomaStatus: Completed, Estimated PCD: 2024-02-21
Clinical trial
A Phase 1 Pharmacokinetic and Pharmacodynamic Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple SclerosisStatus: Active (not recruiting), Estimated PCD: 2027-04-01
Clinical trial
Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)Status: Terminated, Estimated PCD: 2023-02-22
Clinical trial
A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell MalignanciesStatus: Completed, Estimated PCD: 2015-12-01
Clinical trial
Phase I Study of Ublituximab and Umbralisib in Combination With Targeted Immunotherapy in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT) of CLLStatus: Completed, Estimated PCD: 2021-11-04
Clinical trial
A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2022-02-15
Clinical trial
An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody TherapyStatus: Completed, Estimated PCD: 2015-05-01
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of Umbralisib (TGR-1202) in Combination With Ublituximab in Patients With Treatment Naïve Follicular Lymphoma and Small Lymphocytic LymphomaStatus: Terminated, Estimated PCD: 2022-05-16
Clinical trial
A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination With Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304Status: Terminated, Estimated PCD: 2022-05-26
Clinical trial
A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxStatus: Terminated, Estimated PCD: 2022-05-22
Clinical trial
An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple SclerosisStatus: Completed, Estimated PCD: 2022-11-11
Clinical trial
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 (Umbralisib) in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-Delta Inhibitor TherapyStatus: Terminated, Estimated PCD: 2021-06-10